PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides. Our innovative approach enables the identification of peptidomimetic candidates interfering with the hetero- and/or the homodimerization of target receptors.
PeptiMimesis will develop its pipeline against key targets in the fields of oncology and immuno-oncology and is open to initiate collaboration with pharma partners on receptors of interest.
Press Releases
16-02-29 PeptiMimesis: New biotech startup
PeptiMimesis: New biotech startup developing next generation therapeutic peptides in immuno-oncology, oncology and immune diseases
16-03-08 Ipsen and PeptiMimesis partnership
Ipsen and PeptiMimesis announce a research partnership in oncology
16-04-20 PeptiMimesis secures €1.2m ($1.4m) from Cap Innov’Est
The company will launch its breakthrough technology-platform dedicated to identifying next-generation therapeutic peptides
17-03-15 PeptiMimesis receives second tranche of seed funding to further advance its transmembrane peptide pipeline
Cap Innov’Est renews its support for the unique approach to HER2 positive breast cancer–derived brain metastasis